Gradiant Bioconvergence (GBCC) is the world's first organoid-based
target discovery company that discovers new anti-cancer targets by
combining our comprehensive organoid bank and proprietary AI algorithms.

GBCC's patient-derived organoids are established and systematically
managed along with characteristic information such as genome
analysis and drug reactivity. Our proprietary AI algorithm integrates
multifaceted information to derive targets in an unprecedented and innovative way.

GBCC seeks to be a leading company in the development of patient-centered treatments,
starting with the discovery and verification of anti-cancer targets based on
three-dimensional data derived from patients and expanding into an
innovative drug development pipeline in various disease areas.

  • Patient-Derived
    Organoid Banking
  • AI-Driven
    Target Discovery
  • iPSC-Derived
    Organoid Research